D. Jaeger

861 total citations
18 papers, 566 citations indexed

About

D. Jaeger is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, D. Jaeger has authored 18 papers receiving a total of 566 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 4 papers in Surgery and 2 papers in Molecular Biology. Recurrent topics in D. Jaeger's work include Cancer Immunotherapy and Biomarkers (6 papers), Colorectal Cancer Treatments and Studies (4 papers) and CAR-T cell therapy research (2 papers). D. Jaeger is often cited by papers focused on Cancer Immunotherapy and Biomarkers (6 papers), Colorectal Cancer Treatments and Studies (4 papers) and CAR-T cell therapy research (2 papers). D. Jaeger collaborates with scholars based in Germany, United States and Italy. D. Jaeger's co-authors include Gunnar Folprecht, C.-H. Köhne, Ulrich Steger, Wolf O. Bechstein, Jürgen Weitz, Anke Rentsch, Thomas Gruenberger, Torsten Liersch, J.T. Hartmann and T. Suedhoff and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

D. Jaeger

18 papers receiving 559 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
D. Jaeger Germany 10 370 191 115 103 97 18 566
Frédéric Forget United States 13 251 0.7× 67 0.4× 166 1.4× 54 0.5× 104 1.1× 37 516
Liming Wang China 15 197 0.5× 292 1.5× 121 1.1× 252 2.4× 148 1.5× 62 663
Sehhoon Park South Korea 14 291 0.8× 98 0.5× 124 1.1× 69 0.7× 96 1.0× 53 499
J Genollá Spain 11 198 0.5× 52 0.3× 82 0.7× 89 0.9× 105 1.1× 37 447
Matthew Chau Hsien Ng Singapore 14 199 0.5× 45 0.2× 170 1.5× 132 1.3× 159 1.6× 43 455
Emmy Ludwig United States 11 429 1.2× 43 0.2× 126 1.1× 234 2.3× 127 1.3× 32 682
Soung Min Jeon South Korea 13 258 0.7× 34 0.2× 157 1.4× 100 1.0× 260 2.7× 22 592
Cuiling Zhou China 10 253 0.7× 46 0.2× 143 1.2× 29 0.3× 104 1.1× 11 404
Hua‐Jie Dong China 11 129 0.3× 91 0.5× 60 0.5× 20 0.2× 203 2.1× 21 475
Hidehiro Nishi Japan 9 167 0.5× 101 0.5× 49 0.4× 119 1.2× 57 0.6× 13 351

Countries citing papers authored by D. Jaeger

Since Specialization
Citations

This map shows the geographic impact of D. Jaeger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Jaeger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Jaeger more than expected).

Fields of papers citing papers by D. Jaeger

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Jaeger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Jaeger. The network helps show where D. Jaeger may publish in the future.

Co-authorship network of co-authors of D. Jaeger

This figure shows the co-authorship network connecting the top 25 collaborators of D. Jaeger. A scholar is included among the top collaborators of D. Jaeger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Jaeger. D. Jaeger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Charoentong, Pornpimol, Inka Zoernig, María P. Roberti, et al.. (2025). MA04.06 Neoadjuvant Pembrolizumab: Multi-Omics Characterization of the Tumoral Immune Response Reveals Distinct Mechanisms of Action. Journal of Thoracic Oncology. 20(10). S68–S68. 1 indexed citations
2.
Gitto, Lorenzo, et al.. (2023). Quantification and persistence of COVID‐19 virus in recently deceased individuals before and after embalming. Anatomical Sciences Education. 16(5). 802–813. 1 indexed citations
3.
Tabernero, Josep, Fabrice André, Jean‐Yves Blay, et al.. (2022). Phase II multicohort study of atezolizumab monotherapy in multiple advanced solid cancers. ESMO Open. 7(2). 100419–100419. 24 indexed citations
4.
Koerber, Stefan A., Katharina Dendl, Matthias Uhl, et al.. (2021). Novel FAP ligands enable improved imaging contrast in sarcoma patients due to FAPI-PET/CT. European Journal of Nuclear Medicine and Molecular Imaging. 48(12). 3918–3924. 39 indexed citations
5.
Halama, Niels, Anja Williams, Meggy Suarez‐Carmona, et al.. (2020). 1537P Phase I/II study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer. Annals of Oncology. 31. S944–S944. 8 indexed citations
6.
Haag, Georg Martin, Inka Zoernig, Jessica C. Hassel, et al.. (2018). Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1. European Journal of Cancer. 90. 122–129. 13 indexed citations
7.
Díaz, Luis A., Aurélien Marabelle, T.W. Kim, et al.. (2017). Efficacy of pembrolizumab in phase 2 KEYNOTE-164 and KEYNOTE-158 studies of microsatellite instability high cancers. Annals of Oncology. 28. v128–v129. 52 indexed citations
8.
Antonia, Scott, Julie R. Brahmer, Samir N. Khleif, et al.. (2016). Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC). Annals of Oncology. 27. vi421–vi421. 32 indexed citations
9.
Rosenberg, Jonathan E., Petri Bono, Pavlina Spiliopoulou, et al.. (2016). Nivolumab monotherapy in metastatic urothelial cancer (mUC): Updated efficacy by subgroups and safety results from the CheckMate 032 study. Annals of Oncology. 27. vi271–vi271. 2 indexed citations
10.
Fan, Fengjuan, Muhammad Hasan Bashari, Eugenio Morelli, et al.. (2016). The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment. Leukemia. 31(7). 1570–1581. 64 indexed citations
11.
Fan, Fengjuan, Sonia Vallet, Martin Sattler, et al.. (2015). The AP-1 Transcription Factor JunB Promotes Multiple Myeloma (MM) Cell Proliferation, Survival and Drug Resistance in the Bone Marrow Microenvironment. Clinical Lymphoma Myeloma & Leukemia. 15. e215–e215. 2 indexed citations
12.
Folprecht, Gunnar, Thomas Gruenberger, Wolf O. Bechstein, et al.. (2014). Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Annals of Oncology. 25(5). 1018–1025. 174 indexed citations
13.
Wiskemann, Joachim, Peter Dreger, Rainer Schwerdtfeger, et al.. (2013). Efficacy of exercise training in SCT patients-who benefits most?. Bone Marrow Transplantation. 49(3). 443–448. 43 indexed citations
14.
Lorenzen, Sylvie, Stephanie V. Blank, K. Becker, et al.. (2011). Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients.. Journal of Clinical Oncology. 29(15_suppl). 4037–4037. 1 indexed citations
15.
Zörnig, Inka, Thomas Müller, Christopher R. Frei, et al.. (2010). Immunogenicity of SEREX-identified antigens and disease outcome in pancreatic cancer. Cancer Immunology Immunotherapy. 59(9). 1389–1400. 25 indexed citations
16.
Jaeger, D., et al.. (2010). Boost of cable capacity by DVB-C2 considering realistic channel conditions. 30. 19–20. 1 indexed citations
17.
18.
Sanderson, K.J., et al.. (2006). Activity patterns of bats at house roosts near Adelaide. Australian Mammalogy. 28(2). 137–145. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Frédéric Forget Breakdown of academic impact, for papers by Liming Wang Breakdown of academic impact, for papers by Sehhoon Park Breakdown of academic impact, for papers by J Genollá Breakdown of academic impact, for papers by Matthew Chau Hsien Ng Breakdown of academic impact, for papers by Emmy Ludwig Breakdown of academic impact, for papers by Soung Min Jeon Breakdown of academic impact, for papers by Cuiling Zhou Breakdown of academic impact, for papers by Hua‐Jie Dong Breakdown of academic impact, for papers by Hidehiro Nishi
Rankless by CCL
2026